Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic consequence of Fyn knock-out in glioblastoma, and regional heterogeneity of glioblastoma upon single-cell RNA sequencing

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Mus musculus

PROVIDER: GSE188773 | GEO | 2022/01/12

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptomic consequence of Fyn knock-out in glioblastoma

Project description:To investigate the role of Fyn in glioblastoma, transcriptomic comparison between WT and Fyn-KO glioblastoma was done by bulk RNA sequencing.

2021-11-30 | GSE188771 | GEO

Transcriptomic consequence of Fyn knock-out in glioblastoma, and regional heterogeneity of glioblastoma upon single-cell RNA sequencing

Project description:Transcriptomic consequence of Fyn knock-out in glioblastoma, and regional heterogeneity of glioblastoma upon single-cell RNA sequencing

| PRJNA796648 | ENA

Transcriptomic consequence of Fyn knock-out in glioblastoma

Project description:Transcriptomic consequence of Fyn knock-out in glioblastoma

| PRJNA843080 | ENA

Regional heterogeneity of glioblastoma upon single-cell RNA sequencing

Project description:Using spontaneous mouse GBM model, regional dissection of cortical margin, callosal margin, and tumor center was done for single-cell RNA sequencing to investigate molecular characteristics of marginal cancer cells.

2022-01-15 | GSE188772 | GEO

Regional heterogeneity of glioblastoma upon single-cell RNA sequencing

Project description:Regional heterogeneity of glioblastoma upon single-cell RNA sequencing

| PRJNA796656 | ENA

Radiogenomics to characterize regional genetic heterogeneity in glioblastoma.

Project description:BackgroundGlioblastoma (GBM) exhibits profound intratumoral genetic heterogeneity. Each tumor comprises multiple genetically distinct clonal populations with different therapeutic sensitivities. This has implications for targeted therapy and genetically informed paradigms. Contrast-enhanced (CE)-MRI and conventional sampling techniques have failed to resolve this heterogeneity, particularly for nonenhancing tumor populations. This study explores the feasibility of using multiparametric MRI and texture analysis to characterize regional genetic heterogeneity throughout MRI-enhancing and nonenhancing tumor segments.MethodsWe collected multiple image-guided biopsies from primary GBM patients throughout regions of enhancement (ENH) and nonenhancing parenchyma (so called brain-around-tumor, [BAT]). For each biopsy, we analyzed DNA copy number variants for core GBM driver genes reported by The Cancer Genome Atlas. We co-registered biopsy locations with MRI and texture maps to correlate regional genetic status with spatially matched imaging measurements. We also built multivariate predictive decision-tree models for each GBM driver gene and validated accuracies using leave-one-out-cross-validation (LOOCV).ResultsWe collected 48 biopsies (13 tumors) and identified significant imaging correlations (univariate analysis) for 6 driver genes: EGFR, PDGFRA, PTEN, CDKN2A, RB1, and TP53. Predictive model accuracies (on LOOCV) varied by driver gene of interest. Highest accuracies were observed for PDGFRA (77.1%), EGFR (75%), CDKN2A (87.5%), and RB1 (87.5%), while lowest accuracy was observed in TP53 (37.5%). Models for 4 driver genes (EGFR, RB1, CDKN2A, and PTEN) showed higher accuracy in BAT samples (n = 16) compared with those from ENH segments (n = 32).ConclusionMRI and texture analysis can help characterize regional genetic heterogeneity, which offers potential diagnostic value under the paradigm of individualized oncology.

| S-EPMC5193022 | biostudies-literature

Glioblastoma heterogeneity at single cell resolution.

Project description:Glioblastoma (GBM) is one of the deadliest types of cancer and highly refractory to chemoradiation and immunotherapy. One of the main reasons for this resistance to therapy lies within the heterogeneity of the tumor and its associated microenvironment. The vast diversity of cell states, composition of cells, and phenotypical characteristics makes it difficult to accurately classify GBM into distinct subtypes and find effective therapies. The advancement of sequencing technologies in recent years has further corroborated the heterogeneity of GBM at the single cell level. Recent studies have only begun to elucidate the different cell states present in GBM and how they correlate with sensitivity to therapy. Furthermore, it has become clear that GBM heterogeneity not only depends on intrinsic factors but also strongly differs between new and recurrent GBM, and treatment naïve and experienced patients. Understanding and connecting the complex cellular network that underlies GBM heterogeneity will be indispensable in finding new ways to tackle this deadly disease. Here, we present an overview of the multiple layers of GBM heterogeneity and discuss novel findings in the age of single cell technologies.

| S-EPMC10913075 | biostudies-literature

LAMTOR1 interactome upon knock out of USP32

Project description:Ubiquitination is among the most prevalent post-translational modifications regulating a great number of cellular functions, and defects in such processes contribute to many diseases. Deubiquitinating enzymes (DUBs) are essential to control the precise outcome of ubiquitin signals. The ubiquitin-specific protease 32 (USP32) differs from all other DUBs as it comprises in addition to its catalytic USP domain and the DUSP domain also multiple EF hands and a C-terminal prenylation site. This dataset represents an interactome analysis of GFP-tagged LAMTOR1 in human RPE-1 cells upon knock-out of USP32.

2023-01-16 | PXD024940 | Pride

Transcriptomic Heterogeneity in Cancer as a Consequence of Dysregulation of the Gene-Gene Interaction Network.

Project description:Many pathways are dysregulated in cancer. Dysregulation of the regulatory network results in less control of transcript levels in the cell. Hence, dysregulation is reflected in the heterogeneity of the transcriptome: the more dysregulated the pathway, the more the transcriptomic heterogeneity. We identify four scenarios for a transcriptomic heterogeneity increase (i.e., pathway dysregulation) in cancer: (1) activation of a molecular switch, (2) a structural change in a regulator, (3) a temporal change in a regulator, and (4) weakening of gene-gene interactions. These mechanisms are statistically motivated, explored in silico, and their plausibility to occur in vivo illustrated by means of oncogenomics data of breast cancer studies.

| S-EPMC4644214 | biostudies-literature

TSG knock out in hiPSCs

Project description:We will perform RNAseq to evaluate the effects of the loss of a list of TSGs on the transcriptome.

| EGAS00001002262 | EGA